Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.

doi:10.1016/j.ejca.2021.04.009

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.

European journal of cancer (Oxford, England : 1990) - 1 Jul 2021

Carril-Ajuria Lucia, Colomba Emeline, Cerbone Luigi, Romero-Ferreiro Carmen, Crouzet Laurence, Laguerre Brigitte, Thibault Constance, Vicier Cécile, de Velasco Guillermo, Fléchon Aude, Saldana Carolina, Benusiglio Patrick R, Bressac-de Paillerets Brigitte, Guillaud-Bataille Marine, Gaignard Pauline, Scoazec Jean-Yves, Richard Stéphane, Caron Olivier, Escudier Bernard, Albiges Laurence

Abstract excerpt

PURPOSE: Fumarate hydratase-deficient (FHdef) renal cell carcinoma (RCC) is a rare entity associated with the hereditary leiomyomatosis and RCC syndrome with no standard therapy approved. The aim of this retrospective study was to evaluate the efficacy of different systemic treatments in this population. METHODS: We performed a multicentre retrospective analysis of Fhdef RCC patients to determine the response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to France

Share to Fumarate Hydratase

Share to Immune Checkpoint Inhibitors

Share to Kidney Neoplasms

Share to Molecular Targeted Therapy

Share to TOR Serine-Threonine Kinases

Share to Treatment Failure

Source

Open in PubMed

Identifiers

PMID: 33975058
DOI: 10.1016/j.ejca.2021.04.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.PMID 33975058Read ↗

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.Semantic proximity Read ↗

Tislelizumab plus lenvatinib as the first-line therapy in patients with advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, single-centre, phase 2 trial and metabolic biomarker analysisSemantic proximity Read ↗

Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinomaSemantic proximity Read ↗

Fumarate hydratase-deficient renal cell carcinoma: a single institution-based study of 29 patients by clinicopathological, immunohistochemical and genetic approachesSemantic proximity Read ↗

Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approachSemantic proximity Read ↗

Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.Semantic proximity Read ↗

Fumarate hydratase as a therapeutic target in renal cancerSemantic proximity Read ↗

Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaSemantic proximity Read ↗

Case report: Response to immunotherapy and Association with FH gene in Hereditary Leiomyomatosis and Renal Cell Cancer Associated Renal Cell CarcinomaSemantic proximity Read ↗

Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.Semantic proximity Read ↗

Case report: response to immunotherapy and association with the fh gene in hereditary leiomyomatosis and renal cell cancer-associated renal cell cancerSemantic proximity Read ↗

Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.